首页> 美国卫生研究院文献>The EMBO Journal >The alternative product from the human CDKN2A locus p14(ARF) participates in a regulatory feedback loop with p53 and MDM2.
【2h】

The alternative product from the human CDKN2A locus p14(ARF) participates in a regulatory feedback loop with p53 and MDM2.

机译:人类CDKN2A基因座的替代产品p14(ARF)参与了p53和MDM2的调节反馈回路。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The two distinct proteins encoded by the CDKN2A locus are specified by translating the common second exon in alternative reading frames. The product of the alpha transcript, p16(INK4a), is a recognized tumour suppressor that induces a G1 cell cycle arrest by inhibiting the phosphorylation of the retinoblastoma protein by the cyclin-dependent kinases, CDK4 and CDK6. In contrast, the product of the human CDKN2A beta transcript, p14(ARF), activates a p53 response manifest in elevated levels of MDM2 and p21(CIP1) and cell cycle arrest in both G1 and G2/M. As a consequence, p14(ARF)-induced cell cycle arrest is p53 dependent and can be abrogated by the co-expression of human papilloma virus E6 protein. p14(ARF) acts by binding directly to MDM2, resulting in the stabilization of both p53 and MDM2. Conversely, p53 negatively regulates p14(ARF) expression and there is an inverse correlation between p14(ARF) expression and p53 function in human tumour cell lines. However, p14(ARF) expression is not involved in the response to DNA damage. These results place p14(ARF) in an independent pathway upstream of p53 and imply that CDKN2A encodes two proteins that are involved in tumour suppression.
机译:CDKN2A基因座编码的两种不同蛋白质是通过在其他阅读框中翻译共同的第二个外显子来确定的。 α转录产物p16(INK4a)是公认的肿瘤抑制因子,可通过抑制细胞周期蛋白依赖性激酶CDK4和CDK6抑制视网膜母细胞瘤蛋白的磷酸化,从而诱导G1细胞周期停滞。相比之下,人类CDKN2A beta转录产物p14(ARF)激活了M532和p21(CIP1)水平升高中的p53反应,并且在G1和G2 / M中都抑制了细胞周期。结果,p14(ARF)诱导的细胞周期停滞是p53依赖性的,并且可以通过人乳头瘤病毒E6蛋白的共表达而被废除。 p14(ARF)通过直接与MDM2结合而起作用,从而使p53和MDM2都稳定下来。相反,p53负调节p14(ARF)的表达,并且在人类肿瘤细胞系中p14(ARF)的表达与p53的功能呈负相关。但是,p14(ARF)表达不参与对DNA损伤的反应。这些结果将p14(ARF)置于p53上游的独立途径中,并暗示CDKN2A编码参与肿瘤抑制的两种蛋白质。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号